What is the RESILIENCE Study about?
As we age, our immune function declines, leaving us more susceptible to decline in health and the development of diseases including cancer, infections, and chronic inflammatory diseases. This was apparent in the COVID-19 pandemic, in which older adults suffered disproportionally. The RESILIENCE Study is evaluating a new immunomodulator designed to improve natural immune function and health in adults 65 years of age or older.What is the Study evaluating?
Just like our muscles, our innate immune system benefits from training. Our immune system relies on beneficial exposure to bacteria for this training, making our innate immune system stronger and more resilient. The RESILIENCE Study is evaluating an immunomodulator, made from inactivated bacteria, designed to train the immune system and reverse the decline in innate immunity that occurs with aging to maintain health and reduce the risk of infections, cancer, and chronic inflammatory diseases.What does the Study involve?
- Study treatment period of 28 days
- Immune monitoring for an additional 5 months (blood will be collected 5 times)
- Regular interactions and support from clinical study staff
Who can participate?
You may be eligible to participate if you are:- 65 years of age or older
- Living in the Greater Vancouver Area
Who is conducting the Study?
Dr. Theodore Steiner, Professor of Medicine at University of British Columbia, Infectious Diseases Specialist at Vancouver General Hospital, Research Scientist at BC Children’s Hospital Research Institute, and Chief Medical Officer for Infectious Diseases at Qu Biologics, is the Principal Investigator of the Study.
Collaborators
This Study is a collaboration between Qu Biologics, the University of British Columbia, Vancouver Coastal Health Research Institute, and Providence Health Care. This Study is supported by the Canadian government through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).